Dr Amit Oza, Dr Robert Burger and Prof Nicoletta Colombo participate in a roundtable discussion on the treatment of ovarian cancer. They explain how ovarian cancer is currently treated and talk about results of the ICON7 and GOG-218 clinical trials. These trials have evaluated the use of bevacizumab in the treatment of advanced ovarian cancer. Dr Oza and Dr Burger explain the differences between the two trials, the beneficial effects on progression free survival, the adverse effects experienced by patients and discuss which sub-groups of patients responded differently. Nicoletta Colombo discusses with the two trialists how the results should be translated into clinical practice, summarises the conclusions which can be drawn so far with respect to bevacizumab maintenance treatment, discusses the use bevacizumab in up-front treatment and outlines the priorities for further research.